tiprankstipranks
Viking Therapeutics’ Promising Results for Obesity Treatment
Company Announcements

Viking Therapeutics’ Promising Results for Obesity Treatment

Don't Miss our Black Friday Offers:

Viking Therapeutics ( (VKTX) ) just unveiled an announcement.

Viking Therapeutics has presented promising data from its VK2735 obesity program at ObesityWeek® 2024, showcasing up to 8.2% weight loss from baseline with an oral formulation over 28 days. The treatment demonstrated strong tolerability, with mild GI-related side effects, and the potential for longer-term weight loss. These findings are significant for those exploring innovative solutions in metabolic disorder treatments, with both oral and subcutaneous forms of VK2735 showing durable effects.

See more data about VKTX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyViking Therapeutics reports results from Phase 2b clinical trial of VK2809
TheFlyViking to present data from Phase 2b VOYAGE study in late breaker presentation
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App